Repligen Corporation (RGEN)

Market Cap	9.84B
Revenue (ttm)	607.45M
Net Income (ttm)	14.84M
Shares Out	55.88M
EPS (ttm)	0.27
PE Ratio	651.96
Forward PE	107.48
Dividend	n/a
Ex-Dividend Date	n/a

Volume	460,941
Open	174.42
Previous Close	172.48
Day's Range	172.53 - 176.94
52-Week Range	110.45 - 211.13
Beta	1.03
Analysts	Strong Buy
Price Target	199.11 (+13.11%)
Earnings Date	May 1, 2024

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1981
• Employees: 1,783
• Stock Exchange: NASDAQ
• Ticker Symbol: RGEN

Financial Performance

In 2023, Repligen's revenue was $638.76 million, a decrease of -20.31% compared to the previous year's $801.54 million. Earnings were $41.58 million, a decrease of -77.64%.

Analyst Forecast

According to 10 analysts, the average rating for RGEN stock is "Strong Buy." The 12-month stock price forecast is $199.11, which is an increase of 13.11% from the latest price.

Price Target

$199.11

(13.11% upside)

Analyst Consensus: Strong Buy